|
Characteristic
|
Cohort 1
|
Cohort 2
|
|---|
|
Vemurafenib 6 weeks (N = 38)
|
Vemurafenib 7–18 weeks (N = 15)
|
|---|
|
Age (yr)
|
|
Mean (SD)
|
48.6 (12.79)
|
48.5 (13.90)
|
|
Median
|
50.5
|
48.0
|
|
Range
|
21–73
|
26–67
|
|
Gender – no. (%)
|
|
Male
|
15 (39.5)
|
6 (40.0)
|
|
Female
|
23 (60.5)
|
9 (60.0)
|
|
Race – no. (%)
|
|
White
|
35 (92.1)
|
15 (100.0)
|
|
Decline
|
2 (5.3)
|
0 (0.0)
|
|
Other
|
1 (2.6)
|
0 (0.0)
|
|
Metastasis stage – no. (%)
|
|
M1a
|
9 (23.7)
|
2 (13.3)
|
|
M1b
|
13 (34.2)
|
3 (20.0)
|
|
M1c
|
16 (42.1)
|
10 (66.7)
|
|
LDH level – no. (%)
|
|
≤ ULN
|
17 (44.7)
|
5 (33.3)
|
|
> ULN
|
17 (44.7)
|
8 (53.3)
|
|
Not measured
|
4 (10.5)
|
2 (13.3)
|
|
Prior therapy – no. (%)
|
|
Surgery
|
34 (89.5)
|
13 (86.7)
|
|
Radiation
|
7 (18.4)
|
8 (53.3)
|
|
Chemotherapy
|
4 (10.5)
|
1 (6.7)
|
|
Anti-PD1/PDL1
|
0
|
0
|
|
Mutation – no. (%)
|
|
BRAF
|
38 (100.0)
|
15 (100.0)
|
|
cKIT
|
1 (2.6)
|
0 (0.0)
|
|
Other
|
1 (2.6)
|
0 (0.0)
|
|
Performance Status
|
|
0
|
24 (63.2)
|
8 (53.3)
|
|
1
|
14 (36.8)
|
7 (46.7)
|
- Race of ‘Other’ had the description ‘Not specified’ recorded
